Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,008 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Gene expression signatures predict response to therapy with growth hormone.
Stevens A, Murray P, De Leonibus C, Garner T, Koledova E, Ambler G, Kapelari K, Binder G, Maghnie M, Zucchini S, Bashnina E, Skorodok J, Yeste D, Belgorosky A, Siguero JL, Coutant R, Vangsøy-Hansen E, Hagenäs L, Dahlgren J, Deal C, Chatelain P, Clayton P. Stevens A, et al. Pharmacogenomics J. 2021 Oct;21(5):594-607. doi: 10.1038/s41397-021-00237-5. Epub 2021 May 27. Pharmacogenomics J. 2021. PMID: 34045667 Free PMC article. Clinical Trial.
Pharmacogenomics of insulin-like growth factor-I generation during GH treatment in children with GH deficiency or Turner syndrome.
Stevens A, Clayton P, Tatò L, Yoo HW, Rodriguez-Arnao MD, Skorodok J, Ambler GR, Zignani M, Zieschang J, Della Corte G, Destenaves B, Champigneulle A, Raelson J, Chatelain P. Stevens A, et al. Pharmacogenomics J. 2014 Feb;14(1):54-62. doi: 10.1038/tpj.2013.14. Epub 2013 Apr 9. Pharmacogenomics J. 2014. PMID: 23567489 Free PMC article. Clinical Trial.
A pharmacogenomic approach to the treatment of children with GH deficiency or Turner syndrome.
Clayton P, Chatelain P, Tatò L, Yoo HW, Ambler GR, Belgorosky A, Quinteiro S, Deal C, Stevens A, Raelson J, Croteau P, Destenaves B, Olivier C. Clayton P, et al. Among authors: stevens a. Eur J Endocrinol. 2013 Jul 29;169(3):277-89. doi: 10.1530/EJE-13-0069. Print 2013 Sep. Eur J Endocrinol. 2013. PMID: 23761422 Free PMC article. Clinical Trial.
Network analysis: a new approach to study endocrine disorders.
Stevens A, De Leonibus C, Hanson D, Dowsey AW, Whatmore A, Meyer S, Donn RP, Chatelain P, Banerjee I, Cosgrove KE, Clayton PE, Dunne MJ. Stevens A, et al. J Mol Endocrinol. 2013 Dec 19;52(1):R79-93. doi: 10.1530/JME-13-0112. Print 2014 Feb. J Mol Endocrinol. 2013. PMID: 24085748 Review.
3-M syndrome: a growth disorder associated with IGF2 silencing.
Murray PG, Hanson D, Coulson T, Stevens A, Whatmore A, Poole RL, Mackay DJ, Black GC, Clayton PE. Murray PG, et al. Among authors: stevens a. Endocr Connect. 2013 Nov 11;2(4):225-35. doi: 10.1530/EC-13-0065. Print 2013. Endocr Connect. 2013. PMID: 24148222 Free PMC article.
Pediatric perspective on pharmacogenomics.
Stevens A, De Leonibus C, Hanson D, Whatmore A, Murray P, Donn R, Meyer S, Chatelain P, Clayton P. Stevens A, et al. Pharmacogenomics. 2013 Nov;14(15):1889-905. doi: 10.2217/pgs.13.193. Pharmacogenomics. 2013. PMID: 24236488 Review.
Pharmacogenomics related to growth disorders.
Stevens A, De Leonibus C, Whatmore A, Hanson D, Murray P, Chatelain P, Westwood M, Clayton P. Stevens A, et al. Horm Res Paediatr. 2013;80(6):477-90. doi: 10.1159/000355658. Epub 2013 Nov 27. Horm Res Paediatr. 2013. PMID: 24296333 Review.
2,008 results